Results 111 to 120 of about 27,201 (202)

Induction of megakaryocytic differentiation by lapatinib in K562 cells.

, 2013
(A) After 10-µM lapatinib or 1-µM TPA treatment, K562 cells were collected, stained with anti-CD61-FITC, and the fluorescent intensity of FITC in the live cells was analyzed. The percentage of CD61 positive cells for each figure is indicated.
Huey-Lan Huang (336795), Shou-Ping Shih (336799), Yu-Chuen Huang (308321), Yu-Jen Chen (323231), Hsin yi Pan (336798), Yu-Chieh Chen (126845), Kai-Chien Yang (336797)   +6 more
core   +1 more source

Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer

Journal of Experimental & Clinical Cancer Research
Background Basket clinical trials targeting the KRASG12C-mutation in solid tumors have shown initial promise, including in orphan KRASG12C head and neck cancer (HNC).
Ofra Novoplansky, Sankar Jagadeeshan, Manu Prasad, Ksenia M. Yegodayev, Divyasree Marripati, Raghda Abu Shareb, Yariv Greenshpan, Sooraj Mathukkada, Talal Ben-Lulu, Baisali Bhattacharya, Angel Porgador, Dexin Kong, Johannes Brägelmann, J. Silvio Gutkind, Moshe Elkabets   +14 more
doaj   +1 more source

Lapatinib half maximal inhibitory concentration for each cell line.

Lapatinib half maximal inhibitory concentration for each cell line.
Zara Alves Lacerda (18291121), Carlos Eduardo Fonseca-Alves (5374523), Renee Laufer Amorim (7315952), Silvia Regina Rogatto (8058851), Patricia de Faria Lainetti (8058848), Antonio Fernando Leis-Filho (8058845)   +5 more
core   +1 more source

Lapatinib suppresses cysteine deprivation-induced ferroptotic cell death by modulating mitochondrial function. [PDF]

Med Oncol
Kim G, Jang SK, Kim DG, Kim H, Hong J, Park IC, Jin HO.   +6 more
europepmc   +1 more source

Correction: Safety and efficacy of lapatinib, binimetinib, and vinorelbine for RAS mutant metastatic colorectal cancer: results of the RASTRIC Phase I/II trial. [PDF]

Br J Cancer
Huismans MA, Gort EH, van der Heijden LT, Guven Mese SM, Klein Wolterink HM, Braat MNGJA, Elias SG, de Vos FYFL, Devriese LA, Verheul HMW, Opdam FL, Koopman M, Nienhuis HH, Crommelin HA, Snippert HJG, Huitema ADR, Roodhart JML.   +16 more
europepmc   +1 more source

Investigating the Impact of Calcium Channel Blockers on the Pharmacokinetics of Lapatinib: Possible Role of Cytochrome P450 Enzymes and P-glycoprotein Efflux Transporters. [PDF]

Eur J Drug Metab Pharmacokinet
Desai MP, Patil PH, Rajpurohit AUS, Anand VSK, Channabasavaiah JP.   +4 more
europepmc   +1 more source

Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway. [PDF]

Antimicrob Agents Chemother
Sun Z, Huang Y, Guo R, Jiang T, Chen Q, Zhang X, Liu J, Tang Q, Chen M, Huang S.   +9 more
europepmc   +1 more source

Trastuzumab-TKI combination in HER2-Positive tumors: a FAERS-Based safety profile and multimodal analysis of Tanespimycin's role in enhancing targeting of the HSP90AA1-PI3K-Akt-mTOR axis. [PDF]

Front Pharmacol
Chen X, Han X, Zhang Y, Cao J, Wang X.
europepmc   +1 more source

Lapatinib in breast cancer: clinical experiences and future perspectives

, 2010
Lapatinib, an orally available dual inhibitor targeting the tyrosine-kinase domain of both epidermal growth factor receptor-1 and 2, has been introduced for the treatment of advanced/metastatic HER2+ breast cancer in combination with capacitabine after ...
De Laurentiis M, Lorusso V, Tinelli A, Giampaglia M, Chiuri VE, Silvestris N   +5 more
core  

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis. [PDF]

Thorac Cancer
Lin J, Li Q, Zhang P, Fan Y, Cai R, Luo Y, Lan B, Chen S, Wang J, Mo H, Ma F, Wang J, Xu B.   +12 more
europepmc   +1 more source